SAT0272 RITUXIMAB SIGNIFICANTLY DIMINISHES CD86+ B CELLS IN SYSTEMIC SCLEROSIS
Published: Jun 1, 2019
Abstract
Background:
Rituximab (RTX) is a monoclonal antibody that targets the CD20 surface marker. This results in a reduction of CD20+ immune cell populations, foremost B cells. B cell depletion via RTX was found to be beneficial for patients suffering from systemic sclerosis (SSc), leading to an improvement of skin fibrosis and autoimmunity (1,2). However, little is known about the influence of RTX on specific B subsets in SSc....Paper Details
Title
SAT0272 RITUXIMAB SIGNIFICANTLY DIMINISHES CD86+ B CELLS IN SYSTEMIC SCLEROSIS
Published Date
Jun 1, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History